Top 5 Shipping Stocks To Buy Right Now

BY JANE A. PETERSON

In what was touted as Southeast Asia�� biggest private equity deal of 2014, KKR agreed in May to acquire Singapore-listed packaging firm Goodpack for $1.1 billion. The transaction, which awaits court and regulatory approvals, brings a long-awaited payday for Goodpack founder David Lam, who can cash out his 32% stake for $350 million but has an option to buy shares later. Despite the windfall, Lam still falls short of returning to the upper echelon of Singapore wealth; he was last featured on our list in 2008 at No. 40 with a net worth of $120 million. That year, when the financial crisis slammed Goodpack�� shares, Lam failed in an attempt to sell his company. A year later, after he outlined plans to diversify, the shares began to recover, but not quite enough for him to claim a spot on our ever more rarefied Singapore wealth list.

David Lam

An engineer by training, Lam, 62, designed sturdy steel containers after watching wooden crates filled with raw rubber fall to pieces when accidentally dropped from a truck. Lam signed his first client, Goodyear Tire, in 1991 and by 2000 was shipping more rubber than his wood crate rivals.

Hot Machinery Stocks To Invest In 2015: Powershares DB Commodity Index Tracking Fund (DBC)

PowerShares DB Commodity Index Tracking Fund (the Fund) and its subsidiary, DB Commodity Index Tracking Master Fund (the Master Fund), were formed as trusts. The Fund is designed to replicate positions in a commodity index.

The PowerShares DB Commodity Index Tracking Fund is based on the Deutsche Bank Liquid Commodity Index - Optimum Yield Excess Return (Index). The Fund is managed by DB Commodity Services LLC.

Advisors' Opinion:

• [By Richard Stavros]

  Another futures-based ETF is PowerShares Deutsche Bank Commodity Index (DBC). It is more diversified than DBA. It holds futures contracts in corn and wheat. But it also holds significant positions in gold, heating oil, and crude.

• [By Doug Fabian]

  PowerShares DB Commodity Index Tracking Fund (DBC) is a fund that tracks a basket of commodities, including gold, silver, Brent crude oil, RBOB gasoline, heating oil, sugar, corn, soybeans, and much more.

• [By Cameron Swinehart]

  Going forward I will be looking to add investments on my watchlist and trim other positions. It will be interesting to see how an overweight commodity portfolio will perform relative to the rest of the market.

   Cost Basis# SharesCurrent Price% of PortfolioCurrent ValueReturnMetal/Miners      Sprott Physical Gold Trust (PHYS)$12.4985$11.043.75%$938.40-13.13%Sprott Physical Silver Trust (PSLV)$7.95125$8.744.37%$1,092.509.04%FreePort-McMoran (FCX)$31.6731$33.874.20%$1,049.976.50%Ishares MSCI Global Gold Miners ETF (RING)$13.0695$10.644.04%$1,010.80-22.74%Energy      Statoil ASA(STO)$21.7940$22.683.63%$907.203.92%Vanguard Natural Resources LLC (VNR)$27.5636$27.874.01%$1,003.321.11%ConocoPhillips (COP)$63.6822.43$71.006.37%$1,592.5310.31%Agriculture      CVR Partner LP (UAN)$26.3630.9$18.932.34%$584.94-39.25%Adecoagro$6.78125$7.443.72%$930.008.87%Archer-Daniels Midland (ADM)$34.8030$37.244.47%$1,117.206.55%Mixed Commodity      Powershares DB Commodity Index (DBC)$26.3540$25.954.15%$1,038.00-1.54%Sprott Resource Corp$3.34400$2.714.34%$1,084.00-23.25%    Total % of portfolio49.40%               Cost Basis12,666.00      Current Value12,348.86      Return-2.50%  Source: Investing For The Future Surge In Commodity Prices

  Disclosure: I am long ADM, FCX, UAN, AGRO, RING, VNR, SCPZF.PK, COP, DBC, PHYS, PSLV. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)

Top 5 Shipping Stocks To Buy Right Now: Hyperion Therapeutics Inc (HPTX)

Hyperion Therapeutics, Inc. (Hyperion), incorporated in November 2006, is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company develops Ravicti (glycerol phenylbutyrate) to treat the prevalent urea cycle disorders (UCD) and hepatic encephalopathy (HE). The Company has completed two Phase II trials and one pivotal Phase III trial of Ravicti. The Company�� HE clinical program consists of two trials, which have enrolled patients with cirrhosis. On December 23, 2011, the Company submitted a new drug application (NDA) for Ravicti for the chronic management of UCD in patients aged six years and above based on data from its pivotal Phase III trial in adult patients and the results of two Phase II trials, one in adults and one in pediatric patients aged 6 through 17 years. In June 2013, Hyperion Therapeutics Inc announced that the completion of its acquisition of BUPHENYL (sodium phenylbutyrate) Tablets and Powder from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International, Inc.

In June 2011, the Company completed a 24-month carcinogenicity study of Ravicti in rats. On March 22, 2012, pursuant to an asset purchase agreement (purchase agreement) with Ucyclyd Pharma, Inc., a wholly owned subsidiary of Medicis Pharmaceutical Corporation, the Company purchased all of the worldwide rights to Ravicti. The Company also has an option to acquire all of Ucyclyd�� worldwide rights in BUPHENYL and AMMONUL (sodium phenylacetate and sodium benzoate) injection.

The Company conducted a pivotal Phase III trial of Ravicti in adult patients 18 years of age or older with UCD. The Company completed a second Phase II trial at five centers in North America in UCD patients aged 6 through 17 years. This trial includes two phases: a two-week, open-label, safety, tolerability, pharmacokinetic characteristics and ammonia control of Ravicti. The Co! mpany enrolled 77 adult and pediatric UCD patients in its two 12-month open-label safety studies, 69 of whom completed the studies. The Company conducted nonclinical genotoxicity and carcinogenicity studies to assess the tumorigenic potential of Ravicti in animals and to assess the relevant risk in humans. The Company is conducting a Phase II multi-center study of patients with cirrhosis and episodic HE.

Advisors' Opinion:

• [By Sean Williams]

  What: Shares of Hyperion Therapeutics (NASDAQ: HPTX  ) , a biopharmaceutical company focused on treatments for orphan diseases and hepatology, rose as much as 10% after receiving orphan drug exclusivity status for Ravicti from the Food and Drug Administration, and exercising an option to acquire two additional urea cycle drugs from Valeant Pharmaceuticals (NYSE: VRX  ) .

• [By Jesse Solomon]

  NPS Pharmaceuticals (NPSP), for example, created a drug for treating short bowel syndrome. And Hyperion Therapeutics (HPTX) is developing a drug for hepatic encephalopathy, a decline of brain function that according to the National Institute of Health occurs when the liver is no longer able to remove toxins from the blood. Those stocks are up 20% and 40%, respectively, this year.

Top 5 Shipping Stocks To Buy Right Now: Cadence Pharmaceuticals Inc.(CADX)

Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on acquiring, in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada. It holds rights to OFIRMEV injection, a proprietary intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children. The company in-licenses rights to OFIRMEV from Bristol-Myers Squibb Company, which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the Perfalgan brand name. Cadence Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Equities Trading UP
  Cadence Pharmaceuticals (NASDAQ: CADX) shot up 26.42 percent to $14.02 after Mallinckrodt plc (NYSE: MNK) announced its plans to acquire Cadence Pharma for $14.00 per share in cash.

• [By Paul Ausick]

  Stocks on the Move: Zulily Inc. (NASDAQ: ZU) is up 71.4% at $37.70 after its IPO today. Cadence Pharmaceuticals Inc. (NASDAQ: CADX) is up 33.8% at $7.87 on a patent ruling. Electronic Arts Inc. (NASDAQ: EA) is down 7.4% at $24.04.

Top 5 Shipping Stocks To Buy Right Now: The Cheesecake Factory Incorporated(CAKE)

The Cheesecake Factory Incorporated operates upscale, casual, full-service dining restaurants in the United States. As of February 23, 2012, the company operated 170 dining restaurants, including 156 restaurants under The Cheesecake Factory mark in 35 states and the District of Columbia; 13 restaurants under the Grand Lux Cafe mark in 9 states; and 1 restaurant under the RockSugar Pan Asian Kitchen mark in California. It also owns and operates two bakery production facilities located in Calabasas Hills, California; and Rocky Mount, North Carolina. The company produces baked desserts and other products for its restaurants, as well as sells cheesecakes and other baked products on a wholesale basis to other foodservice operators, retailers, and distributors. The Cheesecake Factory Incorporated was founded in 1972 and is based in Calabasas Hills, California.

Advisors' Opinion:

• [By John Dessauer]

  Cheesecake Factory (CAKE) is a financially strong company that is committed to share buybacks. Cheesecake Factory bought back 2.1 million shares at a cost of $90.2 million in the third quarter.